MBX Biosciences draws attention as biotech trends evolve, with analyst views, insider activity, and sector momentum shaping ...

Niagen Bioscience Inc. (NASDAQ:NAGE) is one of the 10 best consumer staples penny stocks to buy now. On April 9, Niagen ...

AUSTIN, Texas, March 30, 2026 /PRNewswire/ -- The Texas Healthcare & Bioscience Institute (THBI), the statewide public policy voice of the healthcare and bioscience industry, today released a ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of ...

More than 100 Butler County leaders, school officials, teachers and high school students saw the official opening ceremony ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of ...

Artelo Biosciences, Inc. ARTL shares jumped on Monday after the company announced the publication of a peer‑reviewed article ...

Octave Bioscience, Inc. is a commercial stage precision care company pioneering biomarker-driven solutions for neurodegenerative diseases, with initial focus on Multiple Sclerosis, and Parkinson’s ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to ...

The Phase 2a study results revealed that VIS-101 produced rapid and durable treatment responses with both 3 mg and 6 mg dose cohorts in patients with wet age-related macular degeneration (wet AMD).

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s ...

Skye Bioscience Inc. (NASDAQ:SKYE) stock sank on Monday after the company released topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab. The nimacimab monotherapy arm did ...